Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
Drug Design, Development and Therapy · 2025-07 · Volume 19 · 5961-5972
DOI: 10.2147/dddt.s527661 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-07. Verfasst von Xue-Qi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Regio…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010050, China.
- Department of Medicine, Division of Radiology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010050, People's Republic of China.
Zitieren
APA
Li, X. Q., Liu, Y., Cai, Z. Y., Lv, T. G., & Hao, J. (2025). Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial. Drug Design, Development and Therapy, Volume 19, 5961-5972. https://doi.org/10.2147/dddt.s527661
Vancouver
Li XQ, Liu Y, Cai ZY, Lv TG, Hao J. Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial. Drug Design, Development and Therapy. 2025;Volume 19:5961-5972. doi:10.2147/dddt.s527661
BibTeX
@article{Li2025,
author = {Li, Xue-Qi and Liu, Yang and Cai, Ze-Yu and Lv, Tie-Gang and Hao, Jian},
title = {Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {5961--5972},
doi = {10.2147/dddt.s527661}
}
EUVIMED